Eric Moessinger

Bio

Eric joined NanoDimension in 2008 and was the first employee of NanoDimension’s Silicon Valley office. He is focused on life sciences investments. Eric is currently board member of Emulate, SQZ Biotech, Serotiny, Amphivena and a board observer of IonPath, Inscripta and Click Diagnostics. He previously observed on the board of ARMO (acquired by Lilly) and Twist (Nasdaq: TWST). Eric also helped lead NanoDimension’s investments in Orca and Octant. Before joining NanoDimension, Eric was a consultant at Bain & Company in Zurich and San Francisco. While at Bain, Eric worked on strategy cases in healthcare, industrial goods and telecommunications and on the turn-around of an electrical component manufacturer. In addition, Eric spent eight months in Bain’s Private Equity Group. Eric has an MS.c. from the London School of Economics and a BS/BA from the University of Florida.